2014
2014-03 aCGT (HK) Founded
2016
2016-03 aCGT (Shanghai) Founded
2017
2017 Research and Production Center for Cell Therapy Products established in Shanghai Thousand Talents Plan Entrepreneurship Park
2019
2019-03 ISO9001:2015 Quality Management System certified
2020
2020-06 Inspection Report obtained from National Institute for Food and Drug Control (China)
2021
2021-10 Kick off meeting of clinical research project with Sichuan Provincial People's Hospital (Liver cirrhosis)
2021-12 Intellectual Property Management System certified
2022
2022-05 1st IND approval (Indication: Acute Respiratory Distress Syndrome, ARDS)
2022-05 2nd IND approval (Indication: Ankylosing Spondylitis, AS)
2022-09 3rd IND approval (Indication: Burn)
2022-12 4th IND approval (Indication: Liver Cirrhosis)
2023
2023-04 1st ARDS patient enrolled
2023-06 4000m² pilot plant completed in Shanghai
2023-04 1st liver cirrhosis patient enrolled
2023-12 All ankylosing spondylitis patients enrolled in Phase I clinical trial
2024
5th CDE IND approval (COPD)
ARDS Phase I completed
AS Phase I completed
Liver cirrhosis Phase I completed
pre-IND with FDA (AS) pre-IND with CDE (iNPC for stroke)
2025
aCGT(USA) founded
pre-IND with CDE (iOPC for spinal cord injury)
Overseas listing structure established
1st AS patient enrolled in Phase II
1st liver cirrhosis patient enrolled in Phase II
IND application to CDE (iNPC for stroke)
iPSC-derived islet cell project launched